Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen Invests $2M in Protedyne; Companies to Co-Market HT Nucleic Acid-Purification Tech

NEW YORK, Feb. 1 (GenomeWeb News) - Qiagen and Protedyne will jointly market the use of Protedyne's BioCube system with Qiagen's QIAamp nucleic acid purification products for use in high-throughput research and molecular diagnostics, the companies said today.

 

In addition, Qiagen will invest approximately $2 million in Protedyne's current Series D financing round, the companies said.

 

Qiagen has exclusive access to BioCube, Protedyne's high-throughput automation platform. The companies originally agreed to develop the high-throughput nucleic acid sample-preparation platform in June 2004.

 

The companies said that the first commercial platform will be available in the second quarter of 2005, at which point both parties are expected to expand their collaboration by adding and validating additional applications.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.